NO20052475L - Acylderivater av 5-(2-(4-(1,2 benzotiazol-3-yl)-1-piperazinyl)etyl)-6-klor-1,3-dihydro-2H-indol-2-on med neuroleptisk aktivitet. - Google Patents

Acylderivater av 5-(2-(4-(1,2 benzotiazol-3-yl)-1-piperazinyl)etyl)-6-klor-1,3-dihydro-2H-indol-2-on med neuroleptisk aktivitet.

Info

Publication number
NO20052475L
NO20052475L NO20052475A NO20052475A NO20052475L NO 20052475 L NO20052475 L NO 20052475L NO 20052475 A NO20052475 A NO 20052475A NO 20052475 A NO20052475 A NO 20052475A NO 20052475 L NO20052475 L NO 20052475L
Authority
NO
Norway
Prior art keywords
piperazinyl
dihydro
chloro
ethyl
acyl derivatives
Prior art date
Application number
NO20052475A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052475D0 (no
Inventor
Timothy Norris
Rob Colon-Cruz
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20052475D0 publication Critical patent/NO20052475D0/no
Publication of NO20052475L publication Critical patent/NO20052475L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20052475A 2002-10-24 2005-05-23 Acylderivater av 5-(2-(4-(1,2 benzotiazol-3-yl)-1-piperazinyl)etyl)-6-klor-1,3-dihydro-2H-indol-2-on med neuroleptisk aktivitet. NO20052475L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42084302P 2002-10-24 2002-10-24
PCT/IB2003/004519 WO2004037819A1 (en) 2002-10-24 2003-10-13 Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity

Publications (2)

Publication Number Publication Date
NO20052475D0 NO20052475D0 (no) 2005-05-23
NO20052475L true NO20052475L (no) 2005-07-25

Family

ID=32176638

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052475A NO20052475L (no) 2002-10-24 2005-05-23 Acylderivater av 5-(2-(4-(1,2 benzotiazol-3-yl)-1-piperazinyl)etyl)-6-klor-1,3-dihydro-2H-indol-2-on med neuroleptisk aktivitet.

Country Status (24)

Country Link
US (1) US7019009B2 (de)
EP (1) EP1556378B1 (de)
JP (1) JP2006505578A (de)
KR (1) KR100755625B1 (de)
CN (1) CN100340557C (de)
AR (1) AR041695A1 (de)
AT (1) ATE383357T1 (de)
AU (1) AU2003269331B2 (de)
BR (1) BR0315516A (de)
CA (1) CA2500485C (de)
CO (1) CO5550441A2 (de)
CY (1) CY1107300T1 (de)
DE (1) DE60318602T2 (de)
DK (1) DK1556378T3 (de)
ES (1) ES2297200T3 (de)
MX (1) MXPA05002734A (de)
NO (1) NO20052475L (de)
NZ (1) NZ566615A (de)
PL (1) PL376721A1 (de)
PT (1) PT1556378E (de)
RU (1) RU2005112254A (de)
TW (1) TW200418850A (de)
WO (1) WO2004037819A1 (de)
ZA (1) ZA200502109B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2551346A1 (en) * 2003-12-31 2005-07-21 Warner-Lambert Company Llc N-substituted piperidine and piperazine derivatives
AU2010266018B2 (en) * 2009-06-25 2014-01-09 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US8686009B2 (en) * 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
CA2802733C (en) * 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2019173230A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
DE69726206T2 (de) * 1996-02-13 2004-04-15 Pfizer Inc. Prodrogen von 5-(2-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-on
AU5301199A (en) * 1998-08-20 2000-03-14 Sumitomo Pharmaceuticals Company, Limited Oxindole derivatives as growth hormone releasers

Also Published As

Publication number Publication date
DE60318602D1 (de) 2008-02-21
EP1556378B1 (de) 2008-01-09
MXPA05002734A (es) 2005-05-23
CO5550441A2 (es) 2005-08-31
BR0315516A (pt) 2005-08-23
AR041695A1 (es) 2005-05-26
PL376721A1 (pl) 2006-01-09
CA2500485A1 (en) 2004-05-06
PT1556378E (pt) 2008-02-21
US7019009B2 (en) 2006-03-28
ZA200502109B (en) 2006-05-31
KR20050065618A (ko) 2005-06-29
ATE383357T1 (de) 2008-01-15
US20040138232A1 (en) 2004-07-15
CN1705663A (zh) 2005-12-07
AU2003269331B2 (en) 2010-02-18
CA2500485C (en) 2010-03-23
EP1556378A1 (de) 2005-07-27
NO20052475D0 (no) 2005-05-23
WO2004037819A1 (en) 2004-05-06
JP2006505578A (ja) 2006-02-16
CN100340557C (zh) 2007-10-03
DE60318602T2 (de) 2009-01-15
NZ566615A (en) 2009-08-28
CY1107300T1 (el) 2012-11-21
DK1556378T3 (da) 2008-03-17
RU2005112254A (ru) 2006-01-20
TW200418850A (en) 2004-10-01
ES2297200T3 (es) 2008-05-01
AU2003269331A1 (en) 2004-05-13
HK1081185A1 (en) 2006-05-12
KR100755625B1 (ko) 2007-09-04

Similar Documents

Publication Publication Date Title
SG170785A1 (en) Benzothiazoles having histamine h3 receptor activity
HUP9902808A2 (hu) 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(1H)-indol-2-on (ziprazidon) mezilát-trihidrát sói, a vegyületek előállítása és dopamin D2 antagonistaként történő alkalmazása
MY119997A (en) Mesylate dihydrate salts of 5-(2-(4-(1, 2-benzisothiazol-3-yl) -1-piperazinyl)-6-chloro-1, 3- dihydro-2h-indol-2-one
ATE303987T1 (de) Phenoxypropylamin-derivate
EA200401136A1 (ru) Предназначенная для перорального применения лекарственная форма для этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его солей
IL106777A (en) Monohydrate of 5-(2-(4-(1, 2-benzisothiazol-3-yl)-1- piperazinyl)-ethyl)-6- chloro-1, 3-dihydro-2h- indole-2-one hydrochloride and pharmaceutical compositions comprising it
IL202047A (en) Trans-4- {2- [4 [(3,2-dichlorophenyl) -piperazine-1-yl] -ethyl} - n-n-dimethylcarbamoyl-cyclohexylamine for use in the treatment of schizophrenia
GEP20135731B (en) Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethyl carbamoyl-cyclohexylamine for acute mania treatment
CY1107300T1 (el) Ακυλικα παραγωγα της 5-(2-(4-(1,2-βενζισοθειαζολ-3-υλο)-1-πιπεραζινυλ)αιθυλο)-6-χλωρο-1,3-διυδρο-2h-ινδολ-2-ονης με νευροληπτικη δραστικοτητα
DK0790236T3 (da) Prolægemidler af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2H-indol-2-on
NO940274D0 (no) 2-(4-(-azolbutyl)-1-piperazinyl)-5-hydroksy-pyrimidinderivater, deres fremstilling og anvendelse som legemidler
AR048948A1 (es) Una composicion farmaceutica antimicobacteriana
UY26568A1 (es) Nuevos derivados de amidas heterocíclicas
DE50013571D1 (de) Arzneimittel zur behandlung von neuropathien
NO20013408L (no) Anvendelse av 2-substituerte 1,2-benzisotiazol-derivater og 3- substituerte tetrahydropyridopyrimidinon-derivater for profylakseog terapi av cerebral ischemi
MEP37108A (en) Stable polymorph of bifeprunox mesilate (7-[4-([1,1'-biphenyl]-3-yl-metheyl)-1-piperazinyl]-2(3h)-benzoxazolone monomethansulfonate
DK1421086T3 (da) 2-(Aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]-naphthalenyl-derivater med antipsykotisk aktivitet
NO20075600L (no) Profylaktisk eller terapeutisk middel mot nattlig atferdsforstyrrelse assosiert med demens
NO20025031L (no) Benzoksazin- og benzotiazinderivater og deres anvendelse i farmasöytiske midler
DE602005010725D1 (de) Indolin-2-one-pyridin-derivate, herstellung und therapeutische verwendung dafür
DE60333268D1 (de) Hydroxymorpholinonderivat und dessen medizinische verwendung
MY109504A (en) Monohydrate of 5-(2-(4-(1,2 benzisothiazol-3-yl)-1- piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2- one hydrochloride
ES2083319A1 (es) Monohidrato de clorhidrato de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil)-6-cloro-1,3-dihidro-2h-indol-2-ona.
UA101341C2 (ru) Терапевтические применения соединений, которые имеют комбинированную активность в отношении sert, 5-нт3 и 5-нт1a

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application